Search clinical trials for: Expanded Access

Total 3617 results

Latin American Cooperative Oncology Group
GlaxoSmithKline

Recruiting

A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America (CONOR)

Ovarian Cancer

Argentina, Brazil
Emory University

Recruiting

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment (REAL TTIME)

Opioid Use | Opioid Abuse

United States
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Peking Union Medical College Hospital

Recruiting

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC (UCDA PBC)

Primary Biliary Cholangitis

China
Duke University

Recruiting

Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension

Total Ankle Arthroplasty | Tourniquet Hypertension | Intraoperative Hypertension | Ankle Fusion

United States
Children's Hospital of Philadelphia

Recruiting

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC (ExpMACs)

Leukemia | Bone Marrow Failure Syndromes | Immunodeficiencies | Inborn Errors of Metabolism | Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

United States
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
Pfizer

Available

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States
Clene Nanomedicine

Available

Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02

Amyotrophic Lateral Sclerosis

United States
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences

No longer available

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Post COVID-19 Syndrome

United States
Ridgeback Biotherapeutics, LP
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Available

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP

Hemorrhagic Fever, Ebola

Congo, The Democratic Republic of the, Sierra Leone
Aveni Foundation

Available

BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Sarcoma | Soft Tissue Sarcoma | Pancreatic Cancer | Osteosarcoma | Chondrosarcoma | Chordoma | Carcinoma of Breast | MPNST (Malignant Peripheral Nerve Sheath Tumor)

United States
Amgen

Available

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Brazil, Japan
Victor Aquino

Temporarily not available

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Transplant-Related Disorder | GVH - Graft Versus Host Reaction

United States
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Multiple Myeloma
Kite, A Gilead Company

Available

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Follicular Lymphoma | Large B-cell Lymphoma

United States, Japan
Servier
Servier Pharmaceuticals, LLC

Available

Vorasidenib Expanded Access Program

Pathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
Kyowa Kirin, Inc.
University of New Mexico Cancer Center

No longer available

Expanded Access for KHK2455

Glioblastoma Multiforme
Osteal Therapeutics, Inc.

Available

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty (APEX-EAP)

Prosthetic-joint Infection
Seelos Therapeutics, Inc.
Massachusetts General Hospital; National Institute of Neurological Disorders... and other collaborators

No longer available

Intermediate-Sized Expanded Access Study

Amyotrophic Lateral Sclerosis

United States
Telix Pharmaceuticals (Innovations) Pty Limited

Available

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Clear Cell Renal Cell Carcinoma

United States
Brainstorm-Cell Therapeutics

No longer available

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

Amyotrophic Lateral Sclerosis

United States
Jazz Pharmaceuticals

Available

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

HER2-Positive Advanced Biliary Tract Cancer

Spain, United States, France, Italy, United Kingdom
University of Michigan

Available

Expanded Access Metreleptin Study

Familial Partial Lipodystrophy

United States
Seagen Inc.

Available

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
Hutchmed

No longer available

Expanded Access Program of Surufatinib

Neuroendocrine Tumors

United States
Blaze Bioscience Inc.

Available

Expanded Access for BLZ-100 (Tozuleristide)
Kite, A Gilead Company

Available

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma

United States
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Available

RAPA-501 Therapy for ALS EAP

Amyotrophic Lateral Sclerosis

United States
Pfizer
Pfizer

Available

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Sickle Cell Disease

United States, Brazil
Rare Thyroid Therapeutics International AB
Egetis Therapeutics; AnovoRx

Available

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

Monocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley Syndrome

United States
Syndax Pharmaceuticals

Available

Expanded Access Program for SNDX-5613

Relapsed/Refractory Acute Leukemia

United States
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
AbbVie

Available

Expanded Access to Bimatoprost (Durysta)

Open-angle Glaucoma
AbbVie

Available

Expanded Access to Venetoclax

Multiple Myeloma | Non-Hodgkin's Lymphoma | Amyloidosis | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Plasma Cell Leukemia
AbbVie

Available

Expanded Access to Elezanumab

Acute Spinal Cord Injury (SCI) | Acute Ischemic Stroke
AbbVie

Available

Expanded Access to ABBV-400

Non-Small Cell Lung Cancer
AbbVie

Available

Expanded Access to Telisotuzumab Vedotin

Non-Small Cell Lung Cancer (NSCLC)

Australia, Hong Kong, Israel, United States, Germany
IGM Biosciences, Inc.

No longer available

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Relapsed/Refractory Non-Hodgkin Lymphomas

Australia, Korea, Republic of, Spain
Agenus Inc.

Available

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Cancer
Kura Oncology, Inc.

Available

Expanded Access to Ziftomenib

Acute Lymphoblastic Leukemia, With Appropriate Mutations | Acute Myeloid Leukemia, With NPM1 Mutations
Epizyme, Inc.

No longer available

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Renal Cell Carcinoma | Malignant Mesothelioma | Chondrosarcoma | Synovial Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumor | Poorly Differentiated Chordoma | Malignant Rhabdoid Tumor of Ovary | Epithelioid Malignant Peripheral Nerve Sheath Tumor | Sinonasal Carcinoma | Spindle Cell Sarcoma | Epithelioid... and other conditions
Kura Oncology, Inc.

Available

Expanded Access to Tipifarnib

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Epizyme, Inc.
WEP Clinical

No longer available

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

Epithelioid Sarcoma
Cellphire Therapeutics, Inc.

No longer available

Thrombosomes for Expanded Access Use

Bleeding
Jonathan H. Waters
HbO2 Therapeutics LLC

Available

Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia

Anemia Severe

United States
Alexion Pharmaceuticals, Inc.

No longer available

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

Non-hodgkin's Lymphoma | Relapsed/Refractory Chronic Lymphocytic Leukemia
Incyte Corporation

Available

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Chronic Graft Vs. Host Disease
Chimerix

Available

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Glioma | H3 K27M

United States

Search clinical trials for: Expanded Access

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations